Stockscreener 앱 받기
3.46
0.29%
-0.01
전일 마감가:
$3.47
열려 있는:
$3.49
하루 거래량:
1.66M
Relative Volume:
0.49
시가총액:
$681.79M
수익:
$71.80M
순이익/손실:
$-183.59M
주가수익비율:
-3.2818
EPS:
-1.0543
순현금흐름:
$-186.52M
1주 성능:
-7.73%
1개월 성능:
-24.62%
6개월 성능:
-51.81%
1년 성능:
-54.47%
1일 변동 폭
$0.00
$0.00
1주일 범위
$3.365
$3.815
52주 변동 폭
$3.365
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
3.46 | 681.79M | 71.80M | -183.59M | -186.52M | -1.0543 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 개시 | Ladenburg Thalmann | Buy |
| 2026-09-23 | 재개 | JP Morgan | Neutral |
| 2026-04-29 | 재개 | Truist | Buy |
| 2026-02-05 | 개시 | BofA Securities | Buy |
| 2025-12-12 | 재확인 | Wedbush | Outperform |
| 2025-12-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-04 | 개시 | Canaccord Genuity | Buy |
| 2025-07-28 | 개시 | Oppenheimer | Outperform |
| 2025-07-16 | 개시 | Citigroup | Buy |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Wedbush | Outperform |
| 2025-02-25 | 개시 | Jefferies | Buy |
| 2024-10-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate? - Kalkine Media
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
Wave Life Sciences stock hits a 52-week low at USD 4.20 - AD HOC NEWS
Wave Life Sciences Names Monika Vnuk Chief Business Officer - citybiz
Wave Life Sciences appoints Monika Vnuk as chief business officer By Investing.com - Investing.com Australia
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - The Manila Times
Wave Life Sciences Appoints Monika Vnuk as Chief Business Officer - Quiver Quantitative
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - GlobeNewswire
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer - Yahoo Finance
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Nigeria
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com Canada
Wave Life Sciences at Cantor conference: RNA editing gains traction - investing.com
Wave Life Sciences at Cantor conference: RNA editing gains traction By Investing.com - Investing.com UK
Wave Life Sciences stock holds steady ahead of Cantor healthcare conference appearance - ad-hoc-news.de
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - GlobeNewswire
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference - Yahoo Finance
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Wave Life Sciences stock trades quietly as investors focus on recent clinical progress - ad-hoc-news.de
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold" - MarketBeat
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - Simply Wall Street
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares - simplywall.st
Wave Life Sciences targets fat loss without sacrificing muscle - Longevity.Technology
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher - Moomoo
Wave Life Sciences (WVE) Pulls Back 5.2% to $5.13 as Support Holds at $4.87Thematic ETF Flow - vinanet.vn
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026) - Stock Titan
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones - Stock Traders Daily
Wave Life Sciences, Inc.: Top Mutual Funds Holders | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Target Price Consensus and Analysts Recommendations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Performance & Quotes, WVE Stock Price on Nasdaq Exchange - marketscreener.com
Wave Life Sciences, Inc.: Fundamental Analysis and Financial Ratings | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc.: Financial Data Forecasts Estimates and Expectations | WVE | US94352A1043 - marketscreener.com
Wave Life Sciences, Inc. Stock (WVE)Quote Nasdaq - marketscreener.com
Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
WAVE Life Sciences Ltd at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Q2 2026 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus
Wave Life Sciences Ltd.: Revenue and Earnings Analysts Forecasts Revisions | WVE | US94352A1043 - marketscreener.com
WVE Q2 2026 Earnings: Wider-than-Expected Loss of $0.34 per Share Highlights Pipeline InvestmentProfit Growth Outlook - https://www.dars.gov.et/
Wave Life Sciences (WVE) Director Adrian Rawcliffe Sells 12,700 Shares, Reducing Stake to Zero - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares - MarketBeat
Ken Takanashi Sells 3,864 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan - Stock Titan
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover - Yahoo Finance
Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales - simplywall.st
Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026) - Stock Titan
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com Canada
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com South Africa
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com Nigeria
Wave Life Sciences at canaccord growth conference: obesity and RNA bets - Investing.com
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Wave Life Sciences Ltd 주식 (WVE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rawcliffe Adrian | Director |
Aug 12 '26 |
Sale |
5.29 |
12,700 |
67,183 |
0 |
| ADRIAN G RAWCLIFFE | Director |
Aug 12 '26 |
Proposed Sale |
5.04 |
12,700 |
64,072 |
0 |
| TAKANASHI KEN | Director |
Aug 11 '26 |
Sale |
6.01 |
3,864 |
23,223 |
20,079 |
| Tan Aik Na | Director |
Aug 11 '26 |
Sale |
6.01 |
432 |
2,596 |
24,968 |
| HEIDI L WAGNER | Director |
Aug 11 '26 |
Proposed Sale |
6.07 |
7,000 |
42,490 |
0 |
| Wagner Heidi L | Director |
Aug 11 '26 |
Sale |
6.01 |
7,000 |
42,070 |
44,930 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 26 '26 |
Buy |
6.08 |
5,305,782 |
32,265,431 |
23,508,791 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
0.00%
자본화:
|
볼륨(24시간):